Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2015 by Taixing People's Hospital
Information provided by (Responsible Party):
Xu Zhang, Taixing People's Hospital
ClinicalTrials.gov Identifier:
First received: March 19, 2012
Last updated: June 5, 2015
Last verified: June 2015
Vitamin D Supplement in patients with CKD stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and CKD progression.

Condition Intervention Phase
Chronic Kidney Disease Stage 1
Chronic Kidney Disease Stage 2
Drug: Calcitriol
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Taixing People's Hospital:

Primary Outcome Measures:
  • Osteoprotegin level [ Time Frame: one year ] [ Designated as safety issue: No ]
    To assess the effect of vitamin D supplementation on osteoprotegin level in CKD patients

Secondary Outcome Measures:
  • Bone mineral density [ Time Frame: one year ] [ Designated as safety issue: No ]
    To assess the effect of vitamin D supplementation on bone mineral density in patients with CKD stage 1 and 2

  • vascular calcification score [ Time Frame: one year ] [ Designated as safety issue: No ]
    To assess the effect of vitamin D supplementation on vascular calcification score through performing lateral abdominal radiography or CT-based techniques in patients with CKD stage 1 and 2

Estimated Enrollment: 300
Study Start Date: July 2015
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: placebo
one pill per day
Experimental: Calcitriol Drug: Calcitriol
0.25 ug per day for one year
Other Name: Rocaltrol


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of CKD stage 1 and 2
  • Age >18 years
  • Ability to provide informed consent

Exclusion Criteria:

  • On vitamin D in past 4 weeks
  • Plans to relocate out of Taixing City in the next one year
  • Serum phosphate >5.5 mg/dl in past 3 months
  • Serum calcium >10.0 mg/dl in past 3 months
  • Cancer
  • Transplanted organ
  • Rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01561222

Contact: Xu Zhang, Bachelor 008-613-905-266-789 dr.zhangxu@tom.com
Contact: Cai-xia Zhao, Master 008-615-896-079-628 zhaocaixia2010@yahoo.cn

China, Jiangsu
Taixing People's Hospital Not yet recruiting
Taixing, Jiangsu, China, 225400
Contact: Xu Zhang, bachelor    008-613-905-266-789    dr.zhangxu@tom.com   
Sponsors and Collaborators
Taixing People's Hospital
  More Information

Responsible Party: Xu Zhang, Zhang Xu, Taixing People's Hospital
ClinicalTrials.gov Identifier: NCT01561222     History of Changes
Other Study ID Numbers: zhangxu2012 
Study First Received: March 19, 2012
Last Updated: June 5, 2015
Health Authority: China: Food and Drug Administration

Keywords provided by Taixing People's Hospital:
Bone mineral density
Vascular calcification

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Bone Density Conservation Agents
Calcium Channel Agonists
Growth Substances
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on May 24, 2016